Current orthodontic treatments are costly, painful, and a huge burden on time and resources for both patients and orthodontists alike, resulting in a lengthy and frustrating start-to-end process.
Biolux’s lead product, OrthoPulse, is overcoming this challenge through an innovative laser therapy approach and user-friendly app for patients and orthodontists, which accelerates the orthodontic process, so that everyone has a reason to smile :)
We’re delighted to invest in their CHF 4.4M Seed Round, alongside Revere Ventures, which is the first and only venture capital fund focused on oral health.
less pain, more gain
Patients seeking orthodontic treatment currently face a long process, often spanning years and multiple inconvenient in-person visits. Meanwhile, orthodontists have the difficult task of ensuring patients are compliant to complex and difficult hygiene requirements.
Biolux’s flagship product, OrthoPulse®, is solving these pain-points through photobiomodulation, also known as low-level laser therapy (LLLT), to enable faster, less-invasive, and easier orthodontic treatment. This innovative treatment accelerates tissue healing and tooth movement during orthodontic treatment, with more than a dozen clinical studies demonstrating shortened treatment timelines of up to 50% and up to 70% reduction in pain for patients, and consequently an up to 50% increase in revenue and profitability for dental practices, thanks to increased patient turnaround.
In addition to the phototherapeutic technology, patients and clinicians benefit from enhanced user experience via a patient companion app and a doctor's portal, ensuring ease of use and information access. The latest funding boost will accelerate the development of a new digital platform, offering real-time monitoring and treatment optimization for an even more seamless integration into the treatment process.
an expanding global market
Backed by compelling science and equipped with regulatory clearance in the EU and US, OrthoPulse is well-positioned to take advantage of the expanding $9bn global orthodontics market. A significant part of this market expansion is due to an increased prevalence of malocclusions accompanied by a growing awareness of treatment options. Likewise, whilst braces and aligners are most commonly associated with pediatric use, an increase of adult patients who are willing and able to pay for faster treatment options is changing the demographic landscape of the market.
The careful attention to user experience and the understanding of the biggest pain points amongst patients and orthodontists is a result of decades of experience in the aligner space on the management team. Founders Marcel Pordes and Herbert Lohner have combined their extensive experience in strategy consulting, turnaround management, and business development to redefine the orthodontic space.
Their positioning has been further supported by a board that includes industry experts with backgrounds at Invisalign and Dental Monitoring.
the next phase of growth
Already empowered by 13 granted patents and additional patents under development, the latest funding will enable Biolux to broaden the product portfolio, whilst also launching a new patient and doctor portal with optimized UX. As a next step, Biolux aims to widen the scope of the application of photobiomodulation within dental care.
Speaking on the investment, Daniel Dillinger said: “Biolux is already transforming orthodontics and delivering exceptional patient outcomes with its FDA-cleared, patented, and commercially successful flagship product, OrthoPulse®. We’re delighted to partner with the Biolux team as they enter the next phase of growth, further enhancing the state-of-the-art user experience to support their rapid scaling and expansion in the U.S. market.”
We look forward to continuing to provide strategic support as the team expands its operations and product offering to transform dental care in Europe and the US!